NCT02898116 2022-10-10
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01625234 2021-10-06
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
Phase 1/2 Completed
NCT03510611 2019-07-24
A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
Betta Pharmaceuticals Co., Ltd.
Phase 1 Completed